Concord Biotech Limited — Q3 FY26 earnings call

Call held 12 Feb 2026

Management summary

Concord Biotech reported a steady Q3 FY26 with 14% YoY revenue growth, primarily driven by strong API sales. While 9-month revenues saw a 5% decline due to H1 headwinds, management expressed optimism for Q4 and beyond, citing recovering order momentum, WHO GMP certification for its injectable facility, and strategic initiatives like its US subsidiary Stellon Biotech. Profitability was impacted by one-off start-up costs, though core EBITDA margins remained robust.

Highlights

  • Revenue of ₹278 crores, up 14% YoY, demonstrating steady performance despite H1 challenges.

  • API revenue grew 24% YoY to ₹219 crores, driven by increased volumes and second source opportunities.

  • EBITDA margin, excluding start-up costs for injectables and US subsidiary, remained strong at 40% for Q3 and 9 months FY26.

  • Injectable facility received WHO GMP certification, enabling sales in the domestic market and contract manufacturing opportunities, with a peak revenue potential of ₹600 crores.

  • Company maintains a zero-debt status with healthy cash and cash equivalents of ₹350 crores as of December 31, 2025.

Concerns

  • 9-month period revenue declined by 5% YoY to ₹729 crores, primarily due to H1 challenges including US tariff dynamics, CDSCO approval delays, and deferral of Middle East tenders.

  • Q3 PAT declined to ₹64 crores from ₹76 crores last year, impacted by new labor costs of ₹3 crores and lower other income.

  • Formulation revenue declined to ₹58 crores in Q3 FY26 from ₹68 crores in Q3 FY25, partly due to API opportunities being captured.

Key financials

2 periods

Headline

  • Revenue
    ₹278 Cr
    YoY +14%
  • API Revenue
    ₹219 Cr
    YoY +24%
  • Formulation Revenue
    ₹58 Cr
    YoY -14.7%
  • EBITDA
    ₹99 Cr
    YoY +1%
  • EBITDA Margin
    35.6%
  • PAT
    ₹64 Cr
    YoY -15.8%

9M

  • Revenue
    ₹729 Cr
    YoY -5%

What they filed

Q1 FY27: revenue up 27.9%, net profit up 41.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue310 244 430 204 247 −20%278 +14%326 −24%261 +28%
EBITDA137 98 190 61 91 −34%102 +4%122 −36%87 +43%
Net profit99 74 142 43 63 −36%68 −8%90 −37%61 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹100 Cr
    • Maintenance capex ₹30 Cr
    • Newer growth projects
    So of course, you're right, there is a level of maintenance capex across which is close to around INR 30 crores, INR 40 crores. We also have some capex, which is going for certain newer projects that we are trying to build on with some of our customers and certain opportunities to kind of grow over the next year. So, there is some bit of capex happening around there in addition to the maintenance capex. ... So, for the year, generally, we have a capex number of around INR 100 crores, INR 150 crores... That's the number generally we have.
  • Debt Gross ₹0 Cr · Net ₹0 Cr · 0.0× EBITDA
    We are a zero-debt company with investments, bank balance and cash and cash equivalents to the tune of INR 350 crores as on December 31, 2025.
  • Liquidity Cash ₹350 Cr
    We are a zero-debt company with investments, bank balance and cash and cash equivalents to the tune of INR 350 crores as on December 31, 2025.

Guidance & targets

Growth

  • Revenue CAGR Growth · Medium-term · Medium confidence 25%
    And in our previous discussions, we have also said that there could be years where you would see these kind of challenging environment because of which we kind of toned it down to, say, a CAGR of 25% once these 2 growth drivers start kicking in at full capacity.

    — Ankur Vaid

Capacity

  • Injectable Facility Peak Revenue Potential Capacity · High confidence INR 600 crores
    The facility has a peak revenue potential of approximately INR 600 crores.

    — Ankur Vaid

Profitability

  • EBITDA Margin (excl. one-offs) Profitability · Q3 and 9 months FY26 · High confidence 40%
    Excluding injectables-related start-up costs and costs associated with our U.S. subsidiary, EBITDA margins remain in the range of 40% for Q3 and 9 months FY '26.

    — Ankur Vaid

Revenue

  • Q4 Performance Revenue · Q4 FY26 · Medium confidence Stronger
    While spillovers from earlier disruptions are expected to materialize gradually with all positive developments across the industry, we believe the Q4 will be stronger.

    — Ankur Vaid

  • FY26 Performance Revenue · FY26 · High confidence Below historical averages
    While FY '26 is expected to remain below our historical averages, primarily due to the challenges encountered in the first half, we anticipate that FY '27 and beyond will reflect a normalization in performance and regaining back the momentum at least to our historical averages.

    — Ankur Vaid

  • Performance Revenue · FY27 and beyond · High confidence Normalization, regaining momentum to historical averages

    — Ankur Vaid

What to watch in Q4 FY26

Injectable Business Scale-up

Coming quarters
Current Temporary margin impact, initial sales of exhibit batches.
Target Gradual normalization of margins, increased commercial sales.

Why it matters

Key driver for future growth and margin improvement, as per management's strategy.

As the injectable business scales up over the coming quarters, we expect this temporary margin impact to gradually normalize.

Risks & concerns

  • Global Trade Uncertainty (US Tariff Dynamics)

    medium

    H1 FY26 challenges due to US tariff dynamics temporarily disrupted customer procurement patterns, though clarified not to apply to generics.

    Management acknowledged

  • Regulatory Approval Delays (CDSCO)

    medium

    Delay in written confirmation from CDSCO impacted sales in the European market for a couple of months, now resolved.

    Management acknowledged

  • Geopolitical Tensions in Middle East

    medium

    Deferment of tender-based supplies to Middle East market due to geopolitical tensions, currently on hold.

    Management acknowledged

  • Temporary Margin Impact from New Initiatives

    medium

    Profitability impacted by start-up costs for injectable facility and US subsidiary (Stellon Biotech), expected to normalize.

    Management acknowledged

Q&A highlights

8 direct
Future Growth Trajectory and Drivers Direct
So historically, if you see, we have grown at around 18% or so. And during our previous many interactions, what we have said is that the way that we look at growth over the next few years is that while the injectables can do a much larger business, but we have considered half of the business over the next 3 to 5 years, which contribute to around 6% growth. And then we had also considered growth coming in from the CDMO because of enough capacities available and considering that how globally India is becoming more favorable for fermentation compared to, say, Europe or China. So, there was a 6% growth that we had kind of taken it over a medium-term period. So, if you put together your baseline growth of 18% and the 6% from injectables and that of CDMO, you reach to 30%.

Provides a detailed breakdown of the company's long-term growth strategy, identifying key drivers (injectables, CDMO) and quantifying their expected contributions to overall CAGR.

Asked by Chintan Sheth

Impact of New Labour Code on Employee Costs Direct
So yes, your understanding is correct. This is a onetime correction that is basis the Labour Code across the industry and the companies. But way forward, it is going to be an incremental normalized cost that we will have. ... No, that will not be materially enough.

Clarifies that the INR 3 crore provision is a one-time retrospective adjustment and future incremental costs from the new Labour Code will not be materially significant, alleviating concerns about margin impact.

Asked by Chintan Sheth

Progress of CDMO Projects and US Tariffs Direct
Yes. So one of our projects is already commercialized in the U.S., and we are already in talks to kind of evaluate it to take it to a global level. So different markets are also being evaluated by our partner. But for now, I think it is primarily the U.S. market. And this is basically an NDA product where our client has launched the product in the U.S. ... So to our understanding, it did not cover the brands which were already launched into the market. We've not read the new fine prints, but even in the earlier stages, what we got the clarity around October, November that it is not going to be impacting the products that have already been launched into the U.S. market.

Provides an update on the commercialization of a key CDMO project in the US and clarifies the limited impact of US tariffs on already launched branded products, addressing potential investor concerns.

Asked by Ritika

Capex Plans for FY26 and Beyond Direct
So, for the year, generally, we have a capex number of around INR 100 crores, INR 150 crores... That's the number generally we have. ... So of course, you're right, there is a level of maintenance capex across which is close to around INR 30 crores, INR 40 crores. We also have some capex, which is going for certain newer projects that we are trying to build on with some of our customers and certain opportunities to kind of grow over the next year.

Clarifies the annual capex range, distinguishing between maintenance and growth-oriented spending, providing insight into future investment plans.

Asked by Ritika

Impact of Injectable Facility and Stellon Costs on Margins Direct
See, injectables would be close to around INR 10 crores to INR 12 crores. And the Stellon cost would range anywhere between INR 5 crores to INR 10 crores per quarter.

Quantifies the specific quarterly costs associated with the new injectable facility and the US subsidiary Stellon, which are impacting current margins, helping investors model future profitability.

Asked by Naman Bagrecha

Strategy for Stellon Biotech and US Market Penetration Direct
So the procedure of already getting the licenses for the U.S. business is already completed. I think now we are gearing up for the launch activities. So, in subsequent few months or so, we should start seeing the launch happening. So, there would be sales realizations coming from Stellon because they are not doing not only for Concord products, but they would also be looking at in-licensing opportunities.

Outlines the near-term strategy for Stellon Biotech, including expected sales realizations and the pursuit of in-licensing opportunities, indicating how the company plans to leverage its US presence.

Asked by Naman Bagrecha

API Growth Drivers and Pricing Trends Direct
So here, it has been all volume growth only. I mean, being in the kind of while I would say that in fermentation products where the kind of competition that we have, there are only maybe 2 or 3 players in the market. But in spite of that, I don't think that you can go with the pricing increase. So it has been mostly or majorly a volume game rather than a price increase way of growing.

Clarifies that API growth is primarily volume-driven rather than price-driven, and that any pricing decline is single-digit and strategic, not a result of intense price pressure.

Asked by Alankar Garude

Cash Balance Clarification Direct
So it would be, there is a correction there. So, it is close to INR 350 crores. ... Total cash and cash equivalent will be INR 350-odd crores, right? Yes.

Corrects a previously stated cash balance figure, providing accurate liquidity information to investors.

Asked by Chintan Sheth

2 min read 7 chapters

Detailed narrative

Q3 FY26 Performance Overview

Concord Biotech reported a revenue of ₹278 crores in Q3 FY26, marking a 14% year-on-year growth. However, for the nine-month period, revenues declined by 5% to ₹729 crores, primarily due to challenges faced in H1 FY26. API revenues were a strong driver, growing 24% YoY to ₹219 crores in Q3, while formulation revenues saw a decline to ₹58 crores from ₹68 crores in the prior year.

Margin Profile and Impact of New Initiatives

The company's reported EBITDA for Q3 FY26 stood at ₹99 crores, resulting in an EBITDA margin of 35.6%. Management clarified that excluding start-up costs associated with the new injectable facility and the US subsidiary, Stellon Biotech, core EBITDA margins remained robust at 40% for both Q3 and the nine-month period. These temporary impacts are expected to normalize as the injectable business scales up in the coming quarters.

Strategic Growth Drivers and Long-Term Outlook

Concord Biotech outlined a long-term growth strategy targeting a 25% CAGR, driven by injectables and CDMO opportunities, each contributing an estimated 6% to growth. The injectable facility, now WHO GMP certified, has a peak revenue potential of ₹600 crores and will initially focus on the domestic market before expanding to emerging markets. The company is also actively pursuing CDMO partnerships and leveraging its US subsidiary, Stellon Biotech, for direct market presence and in-licensing opportunities.

Regulatory and Geopolitical Headwinds

The first half of FY26 was impacted by several external factors, including uncertainties from US tariff dynamics, a delay in CDSCO written confirmation for European market sales, and the deferment of tender-based supplies to the Middle East due to geopolitical tensions. While CDSCO approval was received in November and tariff concerns for generics were clarified, the Middle East situation remains under close monitoring. These headwinds were characterized as timing-related rather than structural.

Capital Allocation and Liquidity

Concord Biotech maintains a zero-debt position, with cash and cash equivalents totaling ₹350 crores as of December 31, 2025. The company's annual capex plan for FY26 and beyond is in the range of ₹100-150 crores, which is a blend of maintenance (₹30-40 crores) and investments in newer growth projects. This disciplined capital allocation supports its expansion initiatives without incurring debt.

Product Pipeline and Market Positioning

The company completed DMFs for Nystatin and Voclosporin last year and plans to launch two new anti-infective products in the current year, targeting niche segments with limited competition. Its non-immunosuppressant portfolio, including anti-infectives, antifungals, and oncology products, follows the same strategy of focusing on complex products with limited competition. API growth is primarily volume-driven, with strategic discounts sometimes offered for larger growth.

Capacity Utilization

For Q3 FY26, Concord Biotech reported varying capacity utilization rates across its units. Unit 1 operated at 81% utilization, while Unit 3 was at 40% and Unit 2 at 27%. These figures provide insight into the operational efficiency and available headroom for future growth across its manufacturing facilities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls